- Home
- MOLN vs IMMP Comparison
MOLN vs IMMP Comparison
Compare MOLN & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- IMMP
- Stock Information
- Founded
- MOLN 2004
- IMMP 1987
- Country
- MOLN Switzerland
- IMMP Australia
- Employees
- MOLN N/A
- IMMP N/A
- Industry
- MOLN
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- MOLN
- IMMP Health Care
- Exchange
- MOLN Nasdaq
- IMMP Nasdaq
- Market Cap
- MOLN 183.2M
- IMMP 211.1M
- IPO Year
- MOLN 2021
- IMMP N/A
- Fundamental
- Price
- MOLN $3.81
- IMMP $1.88
- Analyst Decision
- MOLN
- IMMP Buy
- Analyst Count
- MOLN 0
- IMMP 1
- Target Price
- MOLN N/A
- IMMP $7.00
- AVG Volume (30 Days)
- MOLN 3.2K
- IMMP 726.6K
- Earning Date
- MOLN 05-15-2025
- IMMP 02-27-2025
- Dividend Yield
- MOLN N/A
- IMMP N/A
- EPS Growth
- MOLN N/A
- IMMP N/A
- EPS
- MOLN N/A
- IMMP N/A
- Revenue
- MOLN $2,525,030.00
- IMMP $3,019,249.00
- Revenue This Year
- MOLN N/A
- IMMP $50.37
- Revenue Next Year
- MOLN $866.67
- IMMP N/A
- P/E Ratio
- MOLN N/A
- IMMP N/A
- Revenue Growth
- MOLN N/A
- IMMP 24.11
- 52 Week Low
- MOLN $3.36
- IMMP $1.32
- 52 Week High
- MOLN $12.70
- IMMP $3.05
- Technical
- Relative Strength Index (RSI)
- MOLN 46.07
- IMMP 49.87
- Support Level
- MOLN $3.58
- IMMP $1.88
- Resistance Level
- MOLN $4.11
- IMMP $2.05
- Average True Range (ATR)
- MOLN 0.12
- IMMP 0.12
- MACD
- MOLN -0.02
- IMMP -0.01
- Stochastic Oscillator
- MOLN 33.74
- IMMP 22.22
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.